This post was originally published on this site
ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) 20% HIGHER; announced that it has expanded its current licensing agreement for trofinetide with Neuren Pharmaceuticals to acquire ex-North American rights to the drug as well as global rights in Rett syndrome and Fragile X syndrome to Neuren’s development candidate NNZ-2591. In April of this year, Acadia launched trofinetide in the United States under the brand name DAYBUE as the first and only drug approved for the treatment of Rett syndrome.
Leslie’s Inc (NASDAQ:LESL) 18% LOWER; announced weaker-than-expected preliminary financial results for the third quarter. The company expects preliminary sales for the third quarter of $611 million including a comparable sales decline of (12)%. Gross profit is expected to be $249 to $251 million and gross margin is expected to be approximately 41%. Net income is expected to be $70 to $73 million, Adjusted EBITDA is expected to be $124 to $128 million, Adjusted net income is expected to be $73 to $76 million, and Adjusted diluted earnings per share are expected to be $0.39 to $0.41. (* The revenue consensus is $703.74 million and the EPS consensus is $0.69).
Intuitive Machines Inc (NASDAQ:LUNR) 16% HIGHER; company said it successfully conducted a complete spacecraft test run of its Nova-C lunar lander – a significant technical achievement in the Company’s efforts to completing its lunar lander. The complete spacecraft test run verified Nova-C’s flight software, flight avionics, liquid oxygen and liquid Methane loading, high-pressure helium system performance, propulsion system complete functionality, and culminating in a hot fire of the Nova-C main engine.
Caribou Biosciences Inc (NASDAQ:CRBU) 7% LOWER; announced it has commenced an underwritten public offering of $100 million of shares of its common stock.
Latham Group Inc (NASDAQ:SWIM) 6% LOWER; falls on Leslie’s third quarter warning.
Pool Corporation (NASDAQ:POOL) 5% LOWER; falls on Leslie’s third quarter warning.
